- Home
- NCNA vs TOVX Comparison
NCNA vs TOVX Comparison
Compare NCNA & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCNA | TOVX |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 6.4M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | NCNA | TOVX |
|---|---|---|
| Price | $1.91 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 29.8K | ★ 5.8M |
| Earning Date | 01-01-0001 | 06-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.03 | $0.16 |
| 52 Week High | $10.00 | $1.50 |
Technical Indicators
Market Signals| Indicator | NCNA | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.81 | 41.68 |
| Support Level | $0.05 | $0.17 |
| Resistance Level | $2.27 | $0.26 |
| Average True Range (ATR) | 0.16 | 0.01 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 18.42 | 3.91 |
Price Performance
Historical ComparisonAbout NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.